Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to US$1.9 billion

Hong Kong-listed Sino Biopharmaceutical said on Wednesday it has granted AstraZeneca the rights to develop a drug designed to treat chronic respiratory diseases outside China for total payments of up to US$1.9 billion (HK$14.82 billion).

• Under the deal, AstraZeneca gets an exclusive license to develop, manufacture and commercialize the drug — TQC3721 — outside China, with additional exclusive global rights for certain future development programs.
• Designed to open airways and fight inflammation at the same time, TQC3721 aims to improve lung function and reduce severe flare-ups for patients with long-term respiratory conditions, Sino Biopharmaceutical said.
• The Hong Kong-listed firm is eligible to receive an upfront payment of US$200 million, with additional development and other milestone payments.

Reuters

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗧𝗵𝗲 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗔𝗽𝗽 ↓